Once-Weekly Tirzepatide for Obesity | NEJM

patients with obesity may require medication to achieve substantial weight reduction the type 2 diabetes drug tear zepatite is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist that has been reported to induce weight reduction in patients with diabetes whether terzepatite can induce weight reduction in patients without diabetes has not been assessed in this international phase 3 double-blind randomized trial 2539 adults with obesity or with overweight plus a weight-related complication and without diabetes were assigned to receive subcutaneous terzepatide once weekly at a dose of 5 10 or 15 milligrams or placebo in addition to

lifestyle intervention the first co-primary endpoint the percentage of weight change from baseline to week 72 favored all doses of terzepatite over placebo in particular mean weight reduction ranged from fifteen percent to twenty one percent with terzepatite as compared with three percent with placebo for the second co-primary endpoint the percentage of participants who lost at least five percent of their body weight by week 72 all three doses were again superior to placebo the most common adverse events with terzepatide were gastrointestinal including nausea diarrhea and constipation these events were most often transient and mild to moderate in

severity and occurred mainly during dose escalation the authors conclude that all three doses of terzepatite conferred meaningful and sustained weight reduction in adults with obesity without diabetes full trial results are available at nejm.org you